Adverse event prediction
||This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. (September 2011)|
Predicting adverse events accurately represents a significant challenge to both the pharmaceutical industry and academia, the reason being that our existing knowledge of biology, disease mechanisms (i.e. how a disease affects the healthy state of a human) and drug design is incomplete and sometimes incorrect. On top of that, the biological complexity and differences between living organisms is such that even if a treatment appears to work in the laboratory it may not work in humans.
The occurrence of an adverse event during a clinical trial is a significant event, not only because of the risk to humans but also from a financial point of view for the organization (usually a pharmaceutical company) sponsoring the development of the drug in question. As a result a lot of effort is continuously invested in this area and there are a number of approaches to predicting adverse events including cell line assays, animal models and computer based in silico models.
In silico models are usually developed by extracting interactions and behaviors of biological systems either from the literature or from experimental data on a specific disease or biological system and integrating this information in some kind of a mathematical model that can be used to understand and predict the behavior of a drug in an organism. Another relatively recent method is based on mining the scientific literature and correlating evidence from seemingly unrelated drugs or medical conditions. If done correctly this type of analysis can offer quite good predictive accuracy and significant lead times which translates to lower cost and development times for new drugs.
While in silico methods aim to capture in depth the current knowledge of a biological system or a disease mechanism, they are still subject to the accuracy of that knowledge and may miss information that while seemingly unrelated, could a multiply interconnected complex biological system prove highly relevant. This gap is addressed by the literature-based discovery approach which does not capture details to the same extent but compensates by offering complete coverage of the available knowledge from all potentially related fields.
- Cameron, Scott J.; Sokoll, Lori J.; Laterza, Omar F.; Shah, Sanket; Green, Gary B. (2007). "A multi-marker approach for the prediction of adverse events in patients with acute coronary syndromes". Clinica Chimica Acta 376 (1–2): 168–73. doi:10.1016/j.cca.2006.08.019. PMID 17011538.
- Gutiérrez, Félix; Navarro, Andrés; Padilla, Sergio; Antón, Rosa; Masiá, Mar; Borrás, Joaquín; Martín-Hidalgo, Alberto (2005). "Prediction of Neuropsychiatric Adverse Events Associated with Long-Term Efavirenz Therapy, Using Plasma Drug Level Monitoring". Clinical Infectious Diseases 41 (11): 1648–53. doi:10.1086/497835. PMID 16267739.
- Scheiber, J; Jenkins, JL; Bender, A; Whitebread, S; Hamon, J; Urban, L; Azzaoui, K; Glick, M; Davies, JW (2008). "Side effect profile prediction - early addressing of big pharma's worst nightmare". Chemistry Central Journal 2: S4. doi:10.1186/1752-153X-2-S1-S4.
- Walter, Hauke; Schmidt, Barbara; Werwein, Marianne; Schwingel, Eva; Korn, Klaus (2002). "Prediction of Abacavir Resistance from Genotypic Data: Impact of Zidovudine and Lamivudine Resistance in Vitro and in Vivo". Antimicrobial Agents and Chemotherapy 46 (1): 89–94. doi:10.1128/AAC.46.1.89-94.2002. PMC 126991. PMID 11751116.